tbuckley/cabot-search huggingface dataset:
TCT-42 Transcatheter echo guided Mitral Valve Repair with Neochord Implantation for posterior leaflet disease: Results from Neochord Independent International Registry
Authors: Andrea Colli, Laura Besola, Eleonora Bizzotto, Erica Manzan, Fabio Zucchetta, Demetrio Pittarello, Kestutis Rucinskas, Andrius Aidietis, Vilius Janusauskas, Diana Zakarkaite, Agne Drasutiene, Bernd Danner, Horst Sievert, Katarzyna Kurnicka, Krzystof Wrobel, Stefano Salizzoni, Mauro Rinaldi, Carlo Savini, Davide Pacini, Mariano Cefarelli, Gino Gerosa
Journal: Journal of the American College of Cardiology (2016)
TCT-681 SOLACE AU Study: Interim results at one year of the Edwards SAPIEN XT TM Transcatheter Heart Valve in intermediate risk patients with severe aortic stenosis in Australia
Authors: Darren Walters, Ajay Sinhal, Martin Ng, Gerald Yong, Nigel Jepson, Stephen Worthley, Ronen Gurvitch, Tony Walton, Ravinay Bhindi, Robert Whitbourn
Journal: Journal of the American College of Cardiology (2016)
Expression of JAK2-V617F Kinase Profoundly Dysregulates the Functional Properties of β1 Integrins on Myeloid Cells
Authors: Nibedita Gupta, Felix C Saalfeld, Tina M Schnoeder, Nomusa Mashamba, Stefanie Kliche, Burkhart Schraven, Florian H Heidel, Thomas Fischer
Journal: Blood (2014)
Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study
Authors: Murielle Roussel, Hervé Avet-Loiseau, Philippe Moreau, Anne Huynh, Lotfi Benboubker, Cyrille Hulin, Gerald Marit, Xavier Leleu, Brigitte Pegourie, Christophe Fruchart, Denis Caillot, Anne-Marie Stoppa, Thierry Facon, Jean-Luc Harousseau, Michel Attal
Journal: Blood (2010)
PROSPECTIVE RANDOMIZED CLINICAL STUDY FOR THE TREATMENT OF LATERAL EPICONDYLITIS; COMPARISON AMONG PRP (PLATELET-RICH PLASM), PROLOTHERAPY, PHYSIOTHERAPY AND ESWT
Authors: SH Lhee, JW Kim, JB Jeon, DY Lee
Journal: British Journal of Sports Medicine (2016)

As recent knowledge proved that pathology of lateral epicondylitis is no more an inflammatory condition, but angiofibroblastic degeneration, steroid injection is no more recommended for lateral epicondylitis. It seems to be inappropriate that most of the comparative study used steroid injection as control group, as steroid injection is no more accepted as a treatment option. As control group should be treated with widely accepted proven method, the authors concluded that physiotherapy is the optimal control group treatment in designing prospective randomized control study. Ideal treatment option for lateral epicondylitis should have potential to promote healing of collagen fibres as basic pathology of lateral epicondylitis is the presence of degenerative changes including disorganized collagen fibres. Among recently highlighted treatments which have healing potential theoretically. The authors chose PRP (Platelet-Rich Plasma), prolotherapy and ESWT (Extracorpeal Shockwave Therapy) considering accessibility and national regulations. Consecutive patients who had refractory elbow pain more than 6 months were recruited into the study and randomized into 4 groups. Group A: Physiotherapy, B: ESWT, C: Prolotherapy, D: PRP. A power analysis performed before data collection indicated that a sample size of 200 patients (50 patients per group) will have 80% power which is able to detect 30% difference in DASH scoring system at a significance level of .05 (effect size=0.64). Mean and standard deviation for power analysis was determined according to preliminary study. Mean age was 52 years and mean Follow-up was 29 months (24–39). All 4 groups showed a decrease of DASH score after treatments (A: from 41.2 to 33.2, B: from 41.3 to 28.0, C: from 37.1to 16.3, D: from 41.2 to 10.6). Difference among DASH scores were not significant at initial point, 3 months and 6 months after the treatments (p&gt;0.01). Post hoc comparisons at 18 and 24 months after treatment indicated that DASH score was better in the PRP group (p&lt;0.01) than in the ESWT or the physiotherapy group and in the prolotherapy group (p&lt;0.01) than in the physiotherapy group. In summary, prolotherapy and PRP showed better clinical outcome compared to ESWT and physiotherapy group and PRP showed most superior results.
TCT-287 Current Perspectives and Practices on Chronic Total Occlusion Percutaneous Coronary Interventions
Authors: Siddharth Patel, Rohan Menon, M. Nicholas Burke, Farouc Amin Jaffer, Robert Yeh, Minh Vo, Dimitri Karmpaliotis, Lorenzo Azzalini, Mauro Carlino, Kambis Mashayekhi, Alfredo Galassi, Stéphane Rinfret, Stephen Ellis, Mitul Patel, Bavana Rangan, Aris Karatasakis, Barbara Anna Danek, Judit Karacsonyi, Erica Resendes, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2016)
TCT-153 Acute Stroke During Primary Percutaneous Coronary Intervention For ST Elevation Myocardial Infarction
Authors: Edward Koifman, Hector M. Garcia-Garcia, Sarkis Kiramijyan, Smita Negi, Arie Steinvil, Romain Didier, Toby Rogers, Sang Yeub Lee, Rebecca Torguson, Jiaxiang Gai, Nelson Bernardo, Itshac Itsik Ben-dor, Robert Lager, Rob Gallino, William Suddath, Lowell Satler, Ron Waksman
Journal: Journal of the American College of Cardiology (2016)
TCT-812 Long Term Clinical and Echocardiographic Outcomes following Percutaneous Transluminal Septal Myocardial Ablation for Hypertrophic Obstructive Cardiomyopathy: a 16 Year Single-Centre Australian Experience
Authors: Jason Nogic, Liam McCormick, Youlin Koh, Marek Bak, Robert Gooley, Ian Meredith
Journal: Journal of the American College of Cardiology (2016)
A phase II report of longitudinal bone marker time trends in racially diverse prostate cancer patients receiving zoledronic acid with androgen deprivation
Authors: V. R. Phooshkooru, H. J. Spencer, M. Kohli
Journal: Journal of Clinical Oncology (2006)

14568 Background: Evidence for preventing androgen deprivation (AD) induced osteoporosis with bisphosphonate therapy in prostate cancer patients has emerged largely from trials conducted in caucasian patients. Osteoporosis related skeletal event incidence in African Americans (AA) receiving AD is significantly lower than caucasians and the effect of bisphosphonates therapy uncertain. We conducted a prospective study to evaluate the efficacy of zoledronic acid in preventing osteoporosis in racially diverse population receiving AD. Methods: Asymptomatic, prostate cancer patients (16 caucasians and 6 AA) with normal renal function undergoing AD, started within the last 9 months were randomized to receive (Arm A) CaCO3/vitamin D (500 mg/200U TID) or (Arm B) CaCO3/vitamin D and zoledronic acid (4 mg IV every 3 months for a year). Bone turnover markers including urine N-telopeptide, serum osteocalcin, serum bone specific alkaline phosphatase(BsAP) were serially measured every 3 months and bone mineral density (BMD) measured by DXA at hip, femur, spine and ward’s triangle at 0, 6 and 15 month intervals. Primary endpoint was to obtain BMD changes and bone turnover rates for each treatment arm. Nonparametric methods for analyzing longitudinal data were used to compare DXA-derived BMD measures and bone turnover rate markers in patients receiving zoledronic acid to the control group. Results: Data is presented for 16/22 patients who have completed 15- month follow up. Time trend analysis of bone formation (BsAP, osteocalcin) and resorption (N-telopeptide) markers and DXA measurements of BMD (spine and hip) are shown in the table. Conclusions: This study suggests that zoledronic acid preserves BMD at spine in racially diverse patients and, likewise provides preliminary estimates of BMD changes that occur over 15 months in patients receiving zoledronic acid and placebo. Larger AA cohorts are needed for prospective validation of the observed effect with zoledronic acid. [Table: see text] [Table: see text]
Stromal cells extracted from ovarian cancer express functional multi drugs resistance proteins: ATP bindig casset and Major vault protein
Authors: A. Rafii, P. Mirshahi, A. Simon, A. Faussat, E. Ducros, J. Marie, E. Pujade-Lauraone, J. Soria, M. Mirshahi
Journal: Journal of Clinical Oncology (2006)

2072 Background: Stromal cells play a central role for the growth of tumor cells. The functional contribution of these cells in cancer therapy is poorly understood. Here we studied the presenceofthe proteins ABC (ATP binding Cassette) and MVP (Major vault protein) implicated in the multi drugs resistance (MDR) phenomena in stromal cells isolated from ascitis of patients with ovarian carcinoma. Methods: Stromal cells were extracted from ascitis of patients with ovarian carcinoma. The expression of MDR proteins as p-gp (Permeability-glycoprotein), BCRP (breast cancer resistance protein) and MRPs (multidrug related proteins) as well as LRP (lung resistance protein that is a MVP) was studied by two different technique (immunocytochemistry and flow cytometry) using specific antibodies against these proteins. The functionality of the pumps or efflux, was studied by incorporation of fluorescent probes, Rhodamine 123 and JC1, substrate for p-gp, calcéine-AM substrate for p-gp and MRPs and at last Mitoxantrone substratum of BCRP, in the presence of specific inhibitors: as the cyclosporine HAS, the GG918 and the MK571 for the pumps Pgp, BCRP and MRPs respectively. Then the expression of the genes was assessed by RT-PCR. Results: 1) The expression of the proteins ABC is confirmed by immunocytochemistry and by flow cytometry. The Pgp and LRP proteins were strongly expressed and they are functional, the MRP-1, 2, 3 and BCRP proteins are weakly expressed and the MRP-5 protein is not detected. 2) The RNAm corresponding to all of these proteins is found by RT-PCR in the stromal cells. Conclusions: All of these results suggest that the MDR proteins are present on the cells surface of the tumour cell microenvironnement. The functionality of these proteins allows supposing their implication in the phenomena of multi drugs resistance to chemotherapy. The interaction between cancer cells and stromal cells should be targeted during specific chemotherapy. No significant financial relationships to disclose.
TCT-818 Early Left Ventricular Dysfunction is Associated with Cardiac Allograft Vasculopathy and Late Mortality After Heart Transplantation
Authors: Kozo Okada, Yasuhiro Honda, Helen Luikart, Paul G. Yock, Peter J. Fitzgerald, Alan C. Yeung, Hannah Valantine, Kiran Khush, William Fearon
Journal: Journal of the American College of Cardiology (2016)
Role of the Direct Interaction between Factor VIII C2 and Factor IXa Gla Domain in the Factor Xase Complex.
Authors: Tetsuhiro Soeda, Keiji Nogami, Masahiro Takeyama, Kenichi Ogiwara, Kazuhiko Tomokiyo, Yoichi Sakata, Akira Yoshioka, Midori Shima
Journal: Blood (2007)
Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012)
Authors: Craig S Boddy, Charles L Bennett, LeAnn B Norris, Peter Georgantopoulos, Suhong Luo, Kenneth R Carson
Journal: Blood (2014)
Lichtenstein technique should be used
Authors: D. Pelta, P. Lafferty
Journal: BMJ (1996)

hernia and usually shorter for bilateral or recurrent hernia.The authors' data on return to work are depres- sing, with long median times in both the group that had laparoscopic repair (22 days) and the group that had open repair (28 days), and may reflect undue caution on the part of either the patients or their general practitioners.In my experience, with clear and emphatic advice that it is safe to do so sedentary workers return to work in one week and those who do more physical work in two.Two sentences in the opening paragraph of the section on the outcome measures suggest an initial bias against laparoscopic repair.It seems highly optimistic to have assumed a 0 5% complication rate for open repair (with no supporting data) and highly pessimistic with regard to laparoscopic repair to choose a sample size that would show only a complication rate of 18% or greater.This study falls into the trap of comparing inexperienced laparoscopic hernia repair with experienced open hernia repair.
The CD21low B Cell Population Is Composed of an Anergic and an Immunostimulatory Germinal Center-like B Cell Subset
Authors: Alexander Shimabukuro-Vornhagen, María García Márquez, Rieke Fischer, Kerstin Wennhold, Juliane Iltgen, Sebastian Theurich, Michael S. von Bergwelt-Baildon
Journal: Blood (2014)
Breastfeeding rates in China: a cross-sectional survey and estimate of benefits of improvement
Authors: Zhenyu Yang, Jianqiang Lai, Dongmei Yu, Yifan Duan, Xuehong Pang, Shan Jiang, Ye Bi, Jie Wang, Liyun Zhao, Shian Yin
Journal: The Lancet (2016)
Survival following first line fluorouracil single agent therapy for advanced colorectal cancer in a cancer unit practice in the United Kingdom (UK)
Authors: F. A. Raja, J. A. Bridgewater
Journal: Journal of Clinical Oncology (2005)

3613 Background: In the UK fluorouracil as a single agent is still recommended as first line treatment for patients with advanced colorectal cancer (ACRC). This is the recommendation of the National Institute of Clinical Excellence (NICE) despite the standard use elsewhere of combination therapy the decisions of which are based on the results of published randomised trials. The aim of this study was to assess the validity of the NICE recommendations in the context of a standard cancer unit practice. Methods: 104 patients, all of whom had 5FU single agent as 1st line therapy, were retrospectively studied. Further treatment regimes on progression of disease were also noted. All patients were assessed using CT scans and RECIST criteria. Chemotherapy consisted of the modified de Gramont regime in all cases (Folinic acid 200mg/m2, 5FU bolus 400mg/m2 followed by 5FU 2800mg/m2 intravenously by 48hr infusion repeated every 2 weeks). Results: The response rate for first line fluorouracil was 13% with 31% of patients having stable disease. The median age was 72 years (18–96). The disease progression rate was 56% with the median time to progression being 3 months (range 0–60 months). Overall survival was 12.1 months (95% C.I. 9.92–14.2 months). 49% of patients proceeded to second line treatment with 11% undergoing third line treatment. Conclusions: Our data suggests that, the response rate, uptake of second and third line therapy as well as survival falls short of those from randomised controlled trials. We would propose that institutions such as NICE whose guidelines have significant influence on the funding of new therapies should take into account the “real world” data as well as those from RCTs. This study was funded in part by an educational grant from Aventis No significant financial relationships to disclose.
TCT-535 Coronary computed tomography angiography (CCTA) blood flow model, how we can improve it? Insights based on comparison with intravascular ultrasound (IVUS) tridimensional model.
Authors: Cristiano G. Bezerra, Carlos A. Bulant, Gonzalo Maso Talou, José Mariani, Breno A.A. Falcão, Fábio A. Pinton, Raul A. Feijóo, Antonio E. Filho, Pablo J. Blanco, Pedro A. Lemos
Journal: Journal of the American College of Cardiology (2016)
Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure
Authors: Feng Liu-Smith, Ahmed Majid Farhat, Anthony Arce, Argyrios Ziogas, Thomas Taylor, Zi Wang, Vandy Yourk, Jing Liu, Jun Wu, Archana J. McEligot, Hoda Anton-Culver, Frank L. Meyskens
Journal: Journal of the American Academy of Dermatology (2016)
TCT-280 Does the effectiveness of recanalization of chronic total coronary occlusion depend on the location of obstruction?
Authors: Leszek Bryniarski, Slawomir Surowiec, Lukasz Klima, Michal Terlecki, Piotr Jankowski, Marek Rajzer, Krzysztof Bryniarski, Adam Curylo, Tadeusz Krolikowski, Krzysztof Zmudka, Dariusz Dudek, Danuta Czarnecka
Journal: Journal of the American College of Cardiology (2016)
TCT-472 Comparison biolimus- and everolimus-eluting stents in patients with complex lesions. Five year follow-up from the COMPARE II trial
Authors: Valeria Paradies, George Vlachojannis, Sjoerd H. Hofma, Mario Togni, Nicolas Vazquez, Mariano Valdes, Vassilis Voudris, ton slagboom, Jean-Jacques Goy, Andre Vuilliomenet, Antonio Serra, Ramiro Trillo, Peter Den Heijer, Martin van der Ent, Pieter Smits
Journal: Journal of the American College of Cardiology (2016)
Re: Scott P. Kelly, Philip S. Rosenberg, William F. Anderson, et al. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol 2017;71:195–201
Authors: Sabine D. Brookman-May, Matthias May, Steffen Lebentrau, Theodor Klotz
Journal: European Urology (2016)
Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Jesús F San Miguel, Meletios A Dimopoulos, Edward A. Stadtmauer, S. Vincent Rajkumar, David Siegel, Marie-Laure Bravo, Marta Olesnyckyj, Robert D. Knight, Jerome B. Zeldis, Jean-Luc Harousseau, Donna M. Weber
Journal: Blood (2008)
TCT-819 Clinical Outcome in Patients with Heart Failure and Moderate Aortic Stenosis
Authors: Lennart van Gils, Marie-Annick Clavel, Mara Vollema, Victoria Delgado, Tamim Nazif, Ernest Spitzer, Rebecca Hahn, Jeroen Bax, Martin Leon, Philippe Pibarot, Nicolas Van Mieghem
Journal: Journal of the American College of Cardiology (2016)
TCT-471 Impact of New- versus Early-Generation Drug Eluting Stents in Women according to Age: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration
Authors: Birgit Vogel, Usman Baber, Gennaro Giustino, Samantha Sartori, Gregg Stone, Stephan Windecker, Patrick Serruys, Edoardo Camenzind, Pieter Smits, David Kandzari, George Dangas, Jaya Chandrasekhar, Michela Faggioni, Serdar Farhan, Raban Jeger, Takeshi Kimura, Ghada Mikhail, Rebecca Ortega, Marco Valgimigli, Adnan Kastrati, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
TCT-144 Impact of Thrombus Aspiration in Primary Percutaneous Coronary Intervention On Long-Term Outcome
Authors: Edward Koifman, Hector M. Garcia-Garcia, Sarkis Kiramijyan, Smita Negi, Romain Didier, Arie Steinvil, Toby Rogers, Sang Yeub Lee, Rebecca Torguson, Jiaxiang Gai, Nelson Bernardo, Robert Lager, Itshac Itsik Ben-dor, Rob Gallino, William Suddath, Lowell Satler, Ron Waksman
Journal: Journal of the American College of Cardiology (2016)
GPER (GPR30): A Nongenomic Receptor (GPCR) for Steroid Hormones with Implications for Cardiovascular Disease and Cancer
Authors: Ross D. Feldman, Lee E. Limbird
Journal: The Annual Review of Pharmacology and Toxicology (2016)

Although the rapid effects of steroids, such as estrogen and aldosterone, were postulated originally to be nongenomic, it is now appreciated that activation of such signaling pathways via a steroid-acting G protein–coupled receptor, the G protein estrogen receptor (GPER), has important transcription-dependent outcomes in the regulation of cell growth and programmed cell death secondary to GPER-regulated second-messenger pathways. GPER is expressed ubiquitously and has diverse biological effects, including regulation of endocrine, immune, neuronal, and cardiovascular functions. Perhaps the most biologically important consequences of GPER activation are the regulation of cell growth, migration, and apoptotic cell death. These cell growth regulatory effects, important in cancer biology, are also relevant in the regulation of cardiac and vascular hypertrophy and in the response to ischemia. This review provides a summary of relevant findings of the impact of GPER regulation by either estradiol or aldosterone in in vitro model systems and extends those findings to in vivo studies of direct clinical relevance for development of GPER-directed agents for treatment of cancer and cardiovascular diseases associated with cellular proliferation.
IgG Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease
Authors: Rocco Pastano, Chiara Dell’Agnola, Caterina Bason, Federica Gigli, Cristina Rabascio, Antonio Puccetti, Gianluigi Cetto, Francesco Bertolini, Fedro Alessandro Peccatori, Giovanni Martinelli, Claudio Lunardi
Journal: Blood (2008)
PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy
Authors: Taofeek Owonikoko, Neal Ready, Pieter Postmus, Martin Reck, Solange Peters, Anne Pieters, Giovanni Selvaggi, Justin Fairchild, Ramaswamy Govindan
Journal: Journal of Thoracic Oncology (2016)
Abstract 19419: Anti Atherogenic Effects of Micro RNA - 21
Authors: Rihab E Hamed-Berair, Abhinav Agarwal, Marcin Wysoczynski, Srinivas D Sithu, Nalinie S Wickramasinghe, Millicent G Winner, Aruni Bhatnagar, Yong Li, Sanjay Srivastava
Journal: Circulation (2015)

Micro RNA-21 (miR-21), an evolutionary conserved micro RNA has been implicated in the pathogenesis of restenosis, myocardial infarction and heart failure. However, little is known about the role of miR-21 in atherosclerosis. Our data show that in vitro, LDL, oxidized LDL, acetylated LDL and LPS induced miR-21 by 2-3-fold (P&lt;0.05) and down regulated its target protein PDCD4 in bone marrow derived macrophages (BMDM). Feeding the LDL receptor-knockout (LDLR-KO) mice with western diet (WD, 8-20 weeks) increased the abundance of miR-21 in BMDM by 1.5-fold (P&lt;0.05). Basally, BMDM isolated from miR-21-KO mice showed induction of TNF alpha, interferon gamma, M-CSF, RANTES, IP10 and LIF by (1.5-3.0-fold); increased early and late apoptosis (2-3-fold, P&lt;0.05); and induced PDCD4 and PTEN. We also observed 40% decrease in the survival of F4/80+ cells during differentiation of bone marrow derived cells isolated from miR-21-KO mice. Stimulation of miR-21-KO BMDM with interferon gamma+LPS polarized the macrophages to pro-inflammatory M1 phenotype (increased expression of CD11c and CD86) and decreased IL-10 formation as compared with WT BMDM. Staurosporin and oxidized lipids derived aldehyde 4-hydroxynonenal significantly increased both early and late apoptosis of miR-21-KO BMDM (2-4-fold, P&lt;0.05). This was accompanied by increased cleavage of caspase 3. Characterization of miR-21-KO mice showed 30% decrease in white blood cells and neutrophils in KO mice. However, levels of circulating immune cells and common progenitor cells in bone marrow of miR-21-KO mice were comparable with wild type mice. Transplantation of bone marrow cells from miR-21-KO into LDLR-KO mice, followed by 12 weeks of WD increased the lesion formation (1.7-fold, P&lt;0.05), apoptosis (3-fold, P&lt;0.05) and necrosis (1.6-fold, P&lt;0.05) in the aortic valve of the chimeric mice. This was accompanied by increased accumulation of macrophages in the non-necrotic areas of the lesion and decrease in lesional smooth muscle cells. Plasma cholesterol levels, and lesional collagen and T-cell levels in the miR-21 chimeric mice were comparable with wild type chimeric mice. Collectively, these data suggest that miR-21 prevents atherosclerosis by inhibiting macrophage apoptosis, necrosis and inflammation.
TCT-272 National Trend in Hospitalization Cost for In-patient Single Vessel Percutaneous Coronary Intervention in Patients with and without Diabetes Mellitus in the United States: An Analysis from Nationwide Inpatient Sample from 2006-2011
Authors: Hemang Panchal, Shimin Zheng, Ashraf Abusara, Eunice Mogusu, Timir Paul
Journal: Journal of the American College of Cardiology (2016)
Efficacy and Safety of Using G-CSF on Day before Stem Cell Infusion (Day -1) in Hematopoietic Stem Cell Transplantation (HSCT) -A Single Institution Experience from India.
Authors: P.S.R.K. Sastry, Prasad Narayanan, Alka Khadwal, Ghansyam Biswas, Roshni Bhagwat, Ashish Bakshi, Purvish Parikh
Journal: Blood (2005)